Brief reportSupraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment
Cited by (101)
Complex Arrhythmias Due to Reversible Causes
2019, Cardiac Electrophysiology ClinicsCitation Excerpt :As a result, in the absence of a concomitant AV nodal blocking agent, this slow atrial flutter can be conducted to the ventricle in a 1:1 ratio, resulting in extremely rapid ventricular response. This is associated with aberrant conduction and a bizarre QRS morphology caused by rate-dependent exaggerated intraventricular conduction delays.28 A 70-year-old woman was admitted to the emergency department for shortness of breath and syncope for the past 2 hours (Fig. 14).
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
2018, Journal of the American College of CardiologyRate control in atrial fibrillation
2016, The LancetCitation Excerpt :Intravenous rate-controlling drugs are necessary in haemodynamically unstable patients. It is recommended that rate-controlling drugs are used concomitantly with class IC antiarrhythmic drugs (flecainide and propafenone) because of the propensity for class IC antiarrhythmic drugs to convert atrial fibrillation to atrial flutter, which in turn might then be conducted rapidly to the ventricles (ie, to avoid the so-called proarrhythmic effect).1,85 After an episode of atrial fibrillation, catheter ablation of the accessory pathway is recommended as first-choice therapy.86
Pharmacology and toxicology of Na<inf>v</inf>1.5-class1 antiarrhythmic drugs
2014, Cardiac Electrophysiology Clinics